Jubilant Pharmova Limited (NSE: JUBLPHARMA) reported a Revenue from Operations of ₹1,533.22 Crores, a boost of 18% growth from the previous year. The Net Loss for the business is ₹16.04 Crore from the profit of ₹50.80 Crore year on year. Earnings per Share is -₹0.98 for this quarter.
Jubilant Pharmova Limited Q3 FY23; Revenue Increased By 18%
Tags: pharmaceuticals
Related Post
- Pyramid Technoplast Limited reports Q3 FY26 volume-led growth; margins steady as new capacities ramp up
Pyramid Technoplast Limited (NSE: PYRAMID, BSE: 543969) reported moderate revenue growth in the December quarter,…
-
Dilip Buildcon Limited (NSE: DBL, BSE: 540047) reports Q3 FY26 results as order book hits record high
Dilip Buildcon Limited (NSE: DBL, BSE: 540047) reported its financial results for the quarter and…
-
Edelweiss Financial Services Limited charts multi-year growth across asset management and insurance businesses
Edelweiss Financial Services Limited (NSE: EDELWEISS, BSE: 532922) presented a multi-year snapshot of growth across…